-
公开(公告)号：US20140155371A1
公开(公告)日：2014-06-05
申请号：US14234158
申请日：2012-07-24
IPC分类号： C07D205/08
CPC分类号： C07D205/08 , C07B57/00
摘要： Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.
摘要翻译： 提供了包含式1化合物（依泽替米贝）和脯氨酸或脯氨酸衍生物或其水合物/溶剂化物的混合物的结晶组合物，以及其获得方法。 还公开了纯化依泽替米贝的方法。
-
2.发明申请MULTICOMPONENT SYSTEM OF RESUVASTATIN CALCIUM SALT AND SORBITOL 有权RESIVASASTIN CALCUM盐和SORBITOL多功能体系公开(公告)号：US20130237553A1
公开(公告)日：2013-09-12
申请号：US13574005
申请日：2011-11-21
IPC分类号： C07D239/42 , C07C29/00 , C07C31/26
CPC分类号： C07D239/42 , A61K31/505 , A61K47/26 , A61K47/6941 , C07C29/00 , C07C31/26
摘要： A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and sorbitol. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystal-lization behaviour and stability.
摘要翻译： 新型固体形式的罗苏伐他汀作为活性成分包含双[（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基） - 氨基]嘧啶-5-基 ] - （3R，5S）-3,5-二羟基庚-6-烯酸]和山梨糖醇。 包含两种组分的晶体和少量的水显示出改进的性能，例如晶体化行为和稳定性。
-
公开(公告)号：US09249108B2
公开(公告)日：2016-02-02
申请号：US13574005
申请日：2011-11-21
IPC分类号： C07D239/42 , C07C29/00 , C07C31/26 , A61K31/505 , A61K47/26 , A61K47/48
CPC分类号： C07D239/42 , A61K31/505 , A61K47/26 , A61K47/6941 , C07C29/00 , C07C31/26
摘要： A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and sorbitol. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior and stability.
摘要翻译： 新型固体形式的罗苏伐他汀作为活性成分包含双[（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基） - 氨基]嘧啶-5-基 ] - （3R，5S）-3,5-二羟基庚-6-烯酸]和山梨糖醇。 包含两种组分的晶体和少量的水显示出改进的性能，例如结晶行为和稳定性。
-
公开(公告)号：US08716305B2
公开(公告)日：2014-05-06
申请号：US13643579
申请日：2012-04-16
IPC分类号： A01N43/42 , A61K31/44 , A61K31/505 , C07D239/42
CPC分类号： A61K31/505 , A61K31/11 , A61K47/10 , C07D239/42
摘要： A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.
-
公开(公告)号：US20140031377A1
公开(公告)日：2014-01-30
申请号：US13643579
申请日：2012-04-16
IPC分类号： A61K31/505 , A61K31/11
CPC分类号： A61K31/505 , A61K31/11 , A61K47/10 , C07D239/42
摘要： A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.
-
公开(公告)号：US20120101126A1
公开(公告)日：2012-04-26
申请号：US13280431
申请日：2011-10-25
IPC分类号： A61K31/47 , C07D215/14
CPC分类号： C07D215/14 , C07B2200/13
摘要： The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
摘要翻译： 本发明涉及匹伐他汀半钙盐的新结晶形式，以下称为多晶型A，B，C，D，E和F，以及无定形形式。 此外，本发明涉及制备这些结晶形式的方法和包含这些结晶形式或无定形形式的无定形形式和药物组合物。
-
公开(公告)号：US20060142582A1
公开(公告)日：2006-06-29
申请号：US10544752
申请日：2004-02-02
IPC分类号： C07D215/16
CPC分类号： C07D215/14 , C07B2200/13
摘要： The present invention is directed to new crystalline forms of Pitavastatin hernicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
摘要翻译： 本发明涉及匹伐他汀鞣酸盐的新结晶形式，以下称为多晶型A，B，C，D，E和F，以及无定形形式。 此外，本发明涉及制备这些结晶形式的方法和包含这些结晶形式或无定形形式的无定型形式和药物组合物。
-
8.发明申请公开(公告)号：US20050107359A1
公开(公告)日：2005-05-19
申请号：US10500910
申请日：2003-07-17
IPC分类号： A61K31/55 , C07D223/16
CPC分类号： C07D223/16 , A61K31/55
摘要： The present invention is directed to the polymorphic Form B and the amorphous form of Benazepril hydrochloride. The present invention is also directed to processes for the preparation of Form B and the amorphous form of Benazepril hydrochloride, as well as novel processes for the preparation of Form A. Furthermore, the present invention is directed to pharmaceutical compositions comprising these crystalline forms.
摘要翻译： 本发明涉及多晶型B和无定形贝那普利盐酸盐。 本发明还涉及制备形式B和无定形形式的贝那普利盐酸盐的方法，以及制备形式A的新方法。此外，本发明涉及包含这些结晶形式的药物组合物。
-
公开(公告)号：US20080269315A1
公开(公告)日：2008-10-30
申请号：US12080141
申请日：2008-03-31
IPC分类号： A61K31/40 , C07D207/30
CPC分类号： C07D207/34
摘要： The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form.
摘要翻译： 本发明涉及阿托伐他汀钙的新型多晶型F，其制备方法和包含该结晶形式的药物组合物。
-
公开(公告)号：US20080249149A1
公开(公告)日：2008-10-09
申请号：US10585448
申请日：2005-01-05
申请人： Paul Adriaan Van Der Schaaf , Jorg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
发明人： Paul Adriaan Van Der Schaaf , Jorg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
IPC分类号： A61K31/41 , C07D249/08 , A61P25/06 , A61K31/135
CPC分类号： C07D403/06
摘要： The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.
摘要翻译： 本发明涉及利多曲坦苯甲酸酯的新型多晶型A和B型，其制备方法和包含这些结晶形式的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.024 秒)
